Back to Top
Ichorbio Citations
| Year | Article Title | ichorbio Product Cited |
|---|---|---|
| 2026 | Demir ZEF et al. Focused Ultrasound Thermal Ablation and CD40 Agonism Reprograms Breast Tumor Immunity to Drive Regression and Memory. bioRxiv, 2026, 2026.03.02.708396. | ICH1073 |
| 2026 | Yibo Huo, et al. Hyaluronic acid-mediated artemisinin/ferrocene co-delivery Nanoplatform enhances immune checkpoint blockade response by triggering tumor cell immunogenic cell death via H₂O₂-independent Chemodynamic therapy. J Coll Interf Sci, 2026, 715: 140259. | ICH1183 |
| 2026 | Demir ZEF et al. Focused Ultrasound Thermal Ablation and CD40 Agonism Reprograms Breast Tumor Immunity to Drive Regression and Memory. bioRxiv, 2026, 2026.03.02.708396. | ICH2244 |
| 2026 | Demir ZEF et al, (2026), Focused Ultrasound Thermal Ablation and CD40 Agonism Reprograms Breast Tumor Immunity to Drive Regression and Memory | ICH2244 |
| 2026 | Lee, KY et al. Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment. Theranostics, 2026, 16(1), 17-36. 23 | ICH2257S228P |
| 2026 | Lee, E.J., Song, J., Yoon, S. et al. Matrix-assisted laser desorption/ionization mass spectrometry-based relative quantification of N-glycans in etanercept and its biosimilar using the stable isotope label Girard’s reagent P. Biotechnol Bioproc E, 2026. | ICH4022 |
| 2026 | Lee, K. Y., et al. Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment. Theranostics, 2026, 16(1), 17-36. 23 | ICH5014 |
| 2026 | Lee, K. Y., et al. Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment. Theranostics, 2026, 16(1), 17-36. 23 | ICH5015 |
| 2026 | Kudo-Saito C,et al. ANGPTL3 in the peripheral circulation is associated with resistance to anti-PD1 therapy in advanced gastric cancer. Cancer Res Commun, 2026, 6 (2): 350–358. | ICH5151 |
| 2026 | Pimenta R, Maurer S, Zhong X, et al. A MICA/B GAALIE-mutant antibody elicits potent natural killer cell-driven immunity in solid and hematologic malignancy models. Cell Reports Medicine, 2026, 2666-3791 | ICH1128 |
| 2025 | Gambles, MT et al. Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacy, Nanomedicine: Nanotechnology, Biology and Medicine, Volume 67, 2025, 102825. | ICH1002 |
| 2025 | Li, S. et al. Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. Adv. Healthcare Mater, 2025, e02156. | ICH1002 |
| 2025 | Gambles, MT et al. Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacy, Nanomedicine: Nanotechnology, Biology and Medicine, 2025, Volume 67, 102825. | ICH1011 |
| 2025 | Tang, Dongyang et al. Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer. Cell Reports Medicine, 2025, Volume 6, Issue 7, 102211 | ICH1045 |
| 2025 | M. Stepanechko et al., "Single Treatment Boiling Histotripsy Focused Ultrasound Ablation Neither Negates nor Enhances the Activity of α-CD40 in a Pancreatic Cancer Model," in IEEE Transactions on Biomedical Engineering, 2025, 72, 11: 3404-3418. | ICH1073 |
| 2025 | Rodriguez-Baena, FJ et al. Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases. Cancer Cell, 2025, 43, 3: 413 - 427.e9 | ICH1084 |
| 2025 | Qiu et al. PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation. J Clin Invest. 2025, 136(4):e193354. | ICH1086 |
| 2025 | Ye, Junjie et al. Oncolytic vaccinia virus expressing non-secreted decoy-resistant IL-18 mutein elicits potent antitumor effects with enhanced safety. Molecular Therapy Oncology, 2025, 33, 3, 201022 | ICH1096 |
| 2025 | Braun, LM. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell, 2025, 43, 2: 269 - 291.e19 | ICH1096 |
| 2025 | Shyr, C.-R. et al. Evaluating Therapeutic Efficacy of Intravesical Xenogeneic Urothelial Cell Treatment Alone and in Combination with Chemotherapy or Immune Checkpoint Inhibition in a Mouse Non-Muscle-Invasive Bladder Cancer Model. Cancers, 2025; 17(15):24482025, 17, 2448. | ICH1132 |
| 2025 | Roichman et al. Dietary Fiber Lacks a Consistent Effect on Immune Checkpoint Blockade Efficacy Across Diverse Murine Tumor Models. Cancer Res, 2025, 85 (17): 3335–3347. | ICH1132 |
| 2025 | Braun LM, Zeiser, R. Protocol to study in vivo organ-specific migration of apoptotic splenocytes in mice with tumor and immune checkpoint inhibitor-induced colitis, STAR Protocols, 2025, 6, 2: 103878. | ICH1132 |
| 2025 | Levin, Sapir et al. Immature monocytic cells within tumors differentiate into immunosuppressive cells in resistant tumors to immunotherapy. iScience, 2025, 28, 8: 113141 | ICH1132 |
| 2025 | Patel, A. et al. Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors. Pharmaceutics, 2025, 17, 691. | ICH1132 |
| 2025 | Dai, Y. et al. Humoral determinants of checkpoint immunotherapy. Nature, 2025, 644, 527–536. | ICH1135 |
| 2025 | Tang, D et al. Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer. Cell Rep Med, 2025 6, 7: 102211 | ICH2243 |
| 2025 | Roichman et al. Dietary Fiber Lacks a Consistent Effect on Immune Checkpoint Blockade Efficacy Across Diverse Murine Tumor Models. Cancer Res, 2025, 85 (17): 3335–3347. | ICH2244 |
| 2025 | Braun, LM. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity Cancer Cell, 2025, 43, 2: 269 - 291.e19 | ICH2244 |
| 2025 | Patel, A. et al. Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors. Pharmaceutics, 2025, 17, 691. | ICH2244 |
| 2025 | Ketchemen, JP et al. Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks.EJNMMI Radiopharm Chem, 2025, 10(1):81 | ICH4013 |
| 2025 | Barakat, R., Al-Sarraf, H. & Redzic, Z. Hypoxemia exerts detrimental effects on the choroid plexuses and cerebrospinal fluid system in rats. Fluids Barriers CNS, 2025, 22, 27. | ICH4022 |
| 2025 | Giang, K.A. et al. An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma. Int. J. Mol. Sci. 2025, 26, 5186. | ICH5011 |
| 2025 | Sponheimer M, et al. TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity. J Immunother Cancer, 2025; 13(12):e013024 | ICH5017 |
| 2025 | Fausther-Bovendo, H. et al. Rapid In Vivo Screening of Monoclonal Antibody Cocktails Using Hydrodynamic Delivery of DNA-Encoded Modified Antibodies. Biomedicines, 2025, 13, 637. | ICH5071 |
| 2025 | Arbués A. et al. Soluble immune mediators orchestrate protective in vitro granulomatous responses across Mycobacterium tuberculosis complex lineages eLife, 2025, 13:RP99062. | ICH5133 |
| 2025 | Sponheimer M, et al. TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity. J Immunother Cancer, 2025, 13(12):e013024 | ICH5167 |
| 2025 | Kummer, N. et al. Anti-amyloid antibody effects on Aβ-42 protein aggregates profiled using nanospectroscopy. bioRxiv, 2025.07.17.665305; | ICH5219 |
| 2024 | Saggau C et all Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. Immunity, 2024,57(10):2416-2432.e8. | ICH1024 |
| 2024 | Majewska, J. et al. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells. Nat Cell Biol, 2024, 26, 1336–1345. | ICH1086 |
| 2024 | Majewska, J., Agrawal, A., Mayo, A. et al. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells. Nat Cell Biol, 2024, 26, 1336–1345, . | ICH1091 |
| 2024 | Ye, J. et al. Intratumoral Delivery of Interleukin 9 via Oncolytic Vaccinia Virus Elicits Potent Antitumor Effects in Tumor Models. Cancers, 2024, 16, 1021. | ICH1096 |
| 2024 | Mine et al. TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes. Nature Communications, 2024, 15, Article number: 1337 | ICH1110 |
| 2024 | Benguigui et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell, 2024, 42, 253–265 | ICH1132 |
| 2024 | Braun, LM. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell, 2024, 43, 2: 269 - 291.e19 | ICH1132 |
| 2024 | Unal, B al. Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer. Nat Commun, 2024 15, 8895. | ICH1132UL |
| 2024 | Mine et al. TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes. Nature Communications, 2024, 15, Article number: 1337 | ICH1135 |
| 2024 | Ilija B et al. Persistently primed microglia restrict the reactivation of latent cytomegalovirus at the expense of neuronal synaptic connectivity, 2024, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-5144336/v1] | ICH1141 |
| 2024 | Majewska, J. et al. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells. Nat Cell Biol, 2024, 26, 1336–1345. | ICH2243 |
| 2024 | Gaifem J, et al. Akkermansia muciniphila and Parabacteroides distasonis synergistically protect from colitis by promoting ILC3 in the gut. mBio, 2024, 15:e00078-24. | ICH2243 |
| 2024 | Benguigui et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell, 2024, 42, 253–265 | ICH2244 |
| 2024 | Liang B. et al. Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy. Front Oncol, 2024, 14; 14:1441935. | ICH2244 |
| 2024 | Ketchemen JP et al. Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer. Eur J Nucl Med Mol Imaging, 2024, 51:2070-2084. | ICH4013 |
| 2024 | Giannos, S.A et al. Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits. Pharm Res, 2024, 41, 1247–1256. | ICH4031 |
| 2024 | McElroy, W. & Heger, CD. Development of the SupersonicIEF Method for High-Throughput Charge Variant Analysis. Electrophoresis, 2024 45, 21-22, 1968-1975. | ICH5080 |
| 2023 | Yuan et al. WNT4 promotes macrophage polarization via granulosa cell M-CSF and reduces granulosa cell apoptosis in endometriosis, Cytokine, 2023, Volume 172, 156400. | ICH1026 |
| 2023 | Cao, Y. et al. Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation. J Nanobiotechnol, 2023, 21, 404. | ICH1042 |
| 2023 | Cao, Y. et al. Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation. J Nanobiotechnol, 2023, 21, 404. | ICH1043 |
| 2023 | Pircher, H. et al. MHC I tetramer staining tends to overestimate the number of functionally relevant self-reactive CD8 T cells in the preimmune repertoire. Eur. J. Immunol., 2023, 53: 2350402. | ICH1073 |
| 2023 | Cao, Y. et al. Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation. J Nanobiotechnol, 2023, 21, 404. | ICH1077 |
| 2023 | Chen et al. NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer. Adv. Sci, 2023, 10, 2302705. | ICH1086 |
| 2023 | Lin et al. Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice. Cell Reports, 2023, 42, 7112812 | ICH1086 |
| 2023 | Liang B. et al. SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression. Cancer Research Communications, 2023, 3 (11): 2412–2419. | ICH1091 |
| 2023 | Yang et al. Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration. Journal of Integrative Medicine, 2023, 21, 6: 575-583. | ICH1128 |
| 2023 | Wu TY, 2023, Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment. Journal of Advanced Research, 2023, 46: 159-171. | ICH1132 |
| 2023 | Kauffman et al. PSGL-1 Blockade Induces Classical Activation of Human Tumor-Associated Macrophages. Cancer Research Communications, 2023, 3 (10): 2182–2194. | ICH1132 |
| 2023 | Liang et al. SIX4 Controls STING Expression Enhancing anti-PD-1 Efficacy. Cancer Res Commun. 2023, 3(11):2412-2419. | ICH1132 |
| 2023 | Xu et al. One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade. Cell Chem Biol, 2023, 31, 5: 932-943.e8 | ICH1132 |
| 2023 | Chen et al. A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles. Nature Communications, 2023, 14, Article number: 5576 | ICH1132UL |
| 2023 | Liang B. et al. SIX4 Controls Anti-PD-1 Efficacy by Regulating STING Expression. Cancer Research Communications, 2023, 3 (11): 2412–2419. | ICH2244 |
| 2023 | Travelli et al. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer. J ImmunoTherapy Cancer, 2023, 11:e007010. | ICH2248 |
| 2023 | Gravina, A. et al. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression. Nat Biotechnol, 2023, 41, 717–727. | ICH4002 |
| 2023 | Gravina et al. Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. Cell Stem Cell, 2023, 30, 1538–1548 | ICH4002 |
| 2023 | Iadonato et al. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors. Front Immunol, 2023; 14: 1311658. | ICH4002 |
| 2023 | Narsimhan et al. Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies. Analytical Chemistry, 2023, 95, 44: 16116-16122. | ICH4009 |
| 2023 | Narsimhan et al. Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies. Analytical Chemistry, 2023, 95, 44: 16116-16122. | ICH4011 |
| 2023 | Narsimhan et al. Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies. Analytical Chemistry, 2023, 95, 44: 16116-16122. | ICH4019 |
| 2023 | Lee et al. A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity. Journal of Experimental & Clinical Cancer Research, 2023, 42, 272 | ICH5015 |
| 2023 | Huang et al. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity. J Transl Med, 2023, 21, 346. | ICH5023 |
| 2023 | Mancusi et al. Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation. Int. J. Mol. Sci, 2023, 24(22), 16105 | ICH5025 |
| 2022 | Chuah S. et al. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 3: 683-694. | ICH1094 |
| 2022 | Xiong J. et al. A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin. Nat Commun, 2022, 12: 4820. | ICH1114 |
| 2022 | Chuah S, Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 3: 683-694. | ICH1132 |
| 2022 | Chuah S, Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 3: 683-694. | ICH1137 |
| 2022 | Chuah, S. et al. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. Journal of Hepatology, 2022,77, 3: 683-694. | ICH2244 |
| 2022 | Yamazaki S. et al. IκBζ controls IL-17-triggered gene expression program in intestinal epithelial cells that restricts colonization of SFB and prevents Th17-associated pathologies, Mucosal Immunology, 2022, 15, 6: 1321-1337. | ICH2246 |
| 2022 | Chuah S et al. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. J of Hepopatol, 2022, 77, 3: 387-394. | ICH2251 |
| 2022 | Chuah S et al. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. J of Hepopatol, 2022, 77, 3: 387-394. | ICH2251UL |
| 2022 | Lo, MW et al. SARS-CoV-2 triggers complement activation through interactions with heparan sulfate. Clin Transl Immunol, 2022, 11: e1413 | ICH4005 |
| 2022 | Tikum, A.F. Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates. Pharmaceutics 2022, 14, 1917. | ICH4007 |
| 2022 | Tikum, A.F. Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates. Pharmaceutics 2022, 14, 1917. | ICH4008 |
| 2022 | Pape J et al. RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model osteoclast activation in a human in vitro ameloblastoma-bone model. J Tissue Engineering, 2022, 13:1-10. | ICH4019 |
| 2022 | Dipasquale et al. Biosimilars in Pediatric IBD: Updated Considerations for Disease Management. Biologics, 2022;16:57-66 | ICH4035 |
| 2021 | Liu Y. et al. PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection. Front. Immunol, 2021, 12:727254. | ICH1132 |
| 2021 | Liu 2021, PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection. Front. Immunol, 2021, 12:727254. | ICH2244 |
| 2021 | Parrish II, RH et al. Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterology Insights, 2021, 12(3), 293-301 | ICH4035 |
| Levin, Sapir et al. Immature monocytic cells within tumors differentiate into immunosuppressive cells in resistant tumors to immunotherapy. iScience, Volume 28, Issue 8, 113141 | ICH1132 | |
| Braun, LM. et al. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell, 43, 2: 269 - 291.e19 | ICH2250 | |
| Huang et al. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity. Journal of Translational Medicine | ICH5023 |
Please see below for a full list of ichorbio publications arranged in date order. ichorbio currently has 32 citations in total.
ichorbio Publications for Product Code ICH1026
Citations for Bulk anti-human HLA-DR antibody (L243)
| Yuan et al. | WNT4 promotes macrophage polarization via granulosa cell M-CSF and reduces granulosa cell apoptosis in endometriosis | Cytokine | 2023 |
ichorbio Publications for Product Code ICH1042
Citations for anti-CD4 In Vivo Antibody - Low Endotoxin (GK1.5)
| Cao et al. | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | 2023 |
ichorbio Publications for Product Code ICH1043
Citations for ichorbio's anti-CD8 In Vivo Antibody - Low Endotoxin (YTS-169)
| Cao et al. | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | 2023 |
ichorbio Publications for Product Code ICH1073
Citations for ichorbio's anti-CD40 In Vivo Antibody - Low Endotoxin (FGK4.5)
| Pircher et al. | MHC I tetramer staining tends to overestimate the number of functionally relevant self-reactive CD8 T cells in the preimmune repertoire | European Journal of Immunology | 2023 | ICH1073 |
ichorbio Publications for Product Code ICH1077
Citations for ichorbio's Anti-Mouse CD209b In Vivo Antibody – Low Endotoxin (22D1)
| Cao et al. | Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation | Journal of Nanobiotechnology | 2023 | ICH1077 |
ichorbio Publications for Product Code ICH1086
Citations for ichorbio's anti-PD-L1 In Vivo Antibody - Low Endotoxin (10F.9G2)
| Chen et al. | NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer | Advanced Science | 2023 | ICH1086 |
| Majewska et al. | p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells | bioRxiv | 2023 | ICH1086 |
| Lin et al. | Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice | Cell Reports | 2023 | ICH1086 |
ichorbio Publications for Product Code ICH1094
Citations for ichorbio's anti-CD120a In Vivo Antibody - Low Endotoxin (55R-170)
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH1094 |
ichorbio Publications for Product Code ICH1114
Citations for ichorbio's anti-RANKL In Vivo Antibody - Low Endotoxin (IK22/5)
| Xiong et al. | A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin | Nature Communications | 2022 | ICH1114 |
ichorbio Publications for Product Code ICH1128UL
Citations for ichorbio's anti-NK1.1 In Vivo Antibody - Low Endotoxin (PK136)
| Yang et al. | Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration | Journal of Integrative Medicine | 2023 | ICH1128UL |
ichorbio Publications for Product Code ICH1132
Citations for ichorbio's anti-PD-1 (RMP1-14)
| Wu et al. | Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment | Journal of Advanced Research | 2023 | ICH1132 |
| Kauffman et al. | PSGL-1 Blockade Induces Classical Activation of Human Tumor-Associated Macrophages. | Cancer Research Communications 2023 | 2023 | ICH1132 |
| Liang et al. | SIX4 Controls STING Expression Enhancing anti-PD-1 Efficacy | bioRxiv | 2023 | ICH1132 |
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH1132 |
| Liu et al. | PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection | Frontiers in Immunology | 2021 | ICH1132 |
| Chen et al. | One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade | bioRxiv | 2023 | ICH1132 |
| Chuah et al. | A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles | Nature Communications | 2023 | ICH1132UL |
ichorbio Publications for Product Code ICH1137
Citations for ichorbio's anti-TNFR2 In Vivo Antibody - Low Endotoxin (TR75-54.7)
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH1137 |
ichorbio Publications for Product Code ICH2244
Citations for ichorbio's anti-Rat IgG2a isotype control
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH2244 |
| Liu et al. | PD-1 Blockade Restores the Proliferation of Peripheral Blood Lymphocyte and Inhibits Lymphocyte Apoptosis in a BALB/c Mouse Model of CP BVDV Acute Infection | Frontiers in Immunology | 2021 | ICH2244 |
ichorbio Publications for Product Code ICH2246
Citations for ichorbio's Rat IgG1 Isotype Control for In Vivo - Low Endotoxin (GL113)
| Yamazaki et al. | IκBζ controls IL-17-triggered gene expression program in intestinal epithelial cells that restricts colonization of SFB and prevents Th17-associated pathologies | mucosal immunology | 2022 | ICH2246 |
ichorbio Publications for Product Code ICH2248
Citations for ichorbio's Mouse IgG1 Isotype Control for In Vivo - Low Endotoxin (HKSP84)
| Travelli et al. | Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer | Journal for ImmunoTheraphy of Cancer | 2023 | ICH2248 |
| Majewska et al. | p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells | bioRxiv | 2023 | ICH2248 |
ichorbio Publications for Product Code ICH2251
Citations for ichorbio's Armenian Hamster IgG Isotype Control for In Vivo - Low Endotoxin (PIP)
| Chuah et al. | Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma | Journal of Hepatology | 2022 | ICH2251 |
ichorbio Publications for Product Code ICH4002
Citations for ichorbio's research grade alemtuzumab biosimilar
| Gravina et al. | Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression | Nature Biotechnology | 2023 | ICH4002 |
| Iadonato et al. | A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors | Front Immunol. 2023; 14: 1311658. | 2023 | ICH4002 |
| Gravina et al. | Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. | Cell Stem Cell 30, 1538–1548 | 2023 | ICH4002 |
ichorbio Publications for Product Code ICH4005
Citations for ichorbio's Eculizumab Biosimilar - Research Grade
| Lo et al. | SARS-CoV-2 Triggers Complement Activation through Interactions with Heparan Sulfate | bioRxiv | 2022 | ICH4005 |
ichorbio Publications for Product Code ICH4007
Citations for ichorbio's Matuzumab Biosimilar - Research Grade
| Tikum et al. | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates | Pharmaceutics | 2022 | ICH4007 |
ichorbio Publications for Product Code ICH4008
Citations for ichorbio's Nimotuzumab Biosimilar - Research Grade
| Tikum et al. | Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates | Pharmaceutics | 2022 | ICH4008 |
ichorbio Publications for Product Code ICH4009
Citations for ichorbio's Nivolumab Biosimilar - Research Grade
| Narsimhan et al. | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | 2023 | ICH4009 |
ichorbio Publications for Product Code ICH4011
Citations for ichorbio's Rituximab Biosimilar - Research Grade
| Narsimhan et al. | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | 2023 | ICH4011 |
ichorbio Publications for Product Code ICH4019
Citations for ichorbio's Denosumab Biosimilar - Research Grade
| Narsimhan et al. | Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies | Analytical Chemistry | 2023 | ICH4019 |
| Pape et al. | RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model | Journal of Tissue Engineering | 2022 | ICH4019 |
ichorbio Publications for Product Code ICH4031
Citations for ichorbio's Ranibizumab Biosimilar - Research Grade
| Gupta et al. | Topical Delivery of Ranibizumab drops in Anti-aggregation diluent formula for retinal Delivery in Rabbits | ARVO Annual Meeting Abstract | 2023 | ICH4031 |
ichorbio Publications for Product Code ICH4035
Citations for ichorbio's Vedolizumab Biosimilar - Research Grade
| Dipasquale et al. | Biosimilars in Pediatric IBD: Updated Considerations for Disease Management | Biologics | 2022 | ICH4035 |
| Parrish II, RH | Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary | Gastroenterology Insights | 2021 | ICH4035 |
ichorbio Publications for Product Code ICH5015
Citations for ichorbio's Urelumab Biosimilar - Research Grade
| Lee et al. | A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity | Journal of Experimental & Clinical Cancer Research | 2023 | ICH5015 |
ichorbio Publications for Product Code ICH5023
Citations for ichorbio's Theralizumab Biosimilar - Research Grade
| Huang et al. | A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity | Journal of Translational Medicine | 2023 | ICH5023 |
